UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED) JULY 19, 2006
STEM CELL THERAPY INTERNATIONAL, INC.
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
NEVADA
------
(STATE OR OTHER JURISDICTION OF INCORPORATION)
000-51931 88-0374180
--------- ----------
(COMMISSION FILE NUMBER NUMBER) (IRS EMPLOYER IDENTIFICATION NO.)
2203 NORTH LOIS AVENUE, 9TH FLOOR
TAMPA,FL33607
-------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE:
(813)600-4088
-------------
N/A
(FORMER NAME OR FORMER ADDRESS, IF CHANGED SINCE LAST REPORT)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
Item 4.01. Change in Registrant's Certifying Accountant
(a) Termination of previous independent accountant.
(i) Effective July 19, 2006, the Registrant terminated its prior accounting
firm Pender Newkirk and Company LLP, as its accounting firm and engaged .Aidman,
Piser & Company, Certified Public Accountants, Tampa, FL, as its new auditors
(ii) Pender Newkirk's reports on the Registrant's financial statements for the
past two years have been qualified as to whether the Company would continue as
a going concern.
(iii) During the two most recent fiscal years and through July 31, 2006,
there have been no disagreements between the Registrant and Pender Newkirk on
any matter of accounting principles or practices, financial statement disclosure
or auditing scope of procedure, which disagreements, if not resolved to the
satisfaction of Pender Newkirk, would have caused them to make reference to the
subject matter thereof in their report on the Registrant's financial statements
for such periods.
(iv) During the two most recent fiscal years and through July 31, 2006,
there have been no reportable events (as defined in Item 304(a)(1)(v) of
Regulation S-K.
(b) Engagement of new independent accountant.
The Company has recently engaged Aidman, Piser & Company, Certified Public
Accountants, Tampa, FL, as its new independent accountants and who will audit
the financial statements for the Company's Annual Report on Form 10-KSB for
the year ended March 31, 2007.
Item 9.01 Financial Statements and Exhibits
(c) Exhibits.
16. Letter from Pender Newkirk, addressed to the Securities and Exchange
Commission, regarding its agreement to the statements made herein.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
STEM CELL THERAPY INTERNATIONAL, INC.
(Registrant)
Dated: August 4, 2006 By: /s/Calvin Cao
-----------------
Calvin Cao
Chairman and Chief Executive Officer